Repertoire Immune Medicines has raised $189 million to advance anti-cancer T-cell therapies through the clinic while expanding its immune response drug discovery platform.

BioAge Labs is adding a third program to its pipeline. The new treatment, licensed from Amgen, is designed to combat muscle aging and could be useful in helping older people recover from surgery more quickly, decreasing muscle atrophy after a long hospital stay or, eventually, warding off frailty in older people.

James Chung, a longtime Amgen executive who led global clinical development for autoimmune drug Enbrel, has a new gig. He joins Kyverna Therapeutics as chief medical officer as the company sets its sights on the clinic.

Roche’s gene therapy unit Spark Therapeutics has penned a $645 million-plus biobucks pact with Bayer-backed Senti Biosciences for new tech aimed at tweaking next-gen gene therapies.

Building on a solid year of growth in the life sciences sector with the more than $1 billion acquisition of German robotics manufacturer Ritter? “Ja, bitte!” says Avantor.

With Eli Lilly on its side and a team of executives with a legacy to build on, Jaguar Gene Therapy has wrapped a $139 million series B funding.

Recursion Pharmaceuticals has set terms for a major $306 million IPO as the artificial intelligence biotech eyes a $3 billion valuation.

A phase 2 clinical trial of an essential tremor (ET) drug candidate in development at Biogen and Sage Therapeutics has met its primary endpoint. The trial linked SAGE-324 to the hoped-for improvement on an upper limb tremor score, but the side effects proved to be intolerable to some patients.

Sanofi has paid $160 million upfront to buy a preclinical biotech that is using mRNA to reprogram immune cells inside the human body. The technology could enable patients to make their own CAR-T cells, eliminating the complex cell therapy supply chain while improving safety and dosing.

PARP inhibitors such as Merck and AstraZeneca’s Lynparza have changed the game for patients with ovarian cancer, but they’re still not a cure, as cancers can outsmart these drugs and develop resistance. Zentalis Pharmaceuticals is developing a WEE1 inhibitor that it hopes to combine with PARP inhibitors and other cancer medicines to boost their efficacy—and its early phase 1 data are promising.